Business Context and Reporting Period
This Form 8-K is a current report filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on June 13, 2022. The filing covers corporate governance events occurring at the 2022 Annual Meeting of Stockholders held on June 13, 2022, and a subsequent Board action on June 15, 2022.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting results.
Material Changes and Corporate Actions
- Bylaws Amendment: On June 15, 2022, the Board approved an amendment to the Company's Bylaws. The quorum requirement for stockholder meetings was increased from one-third to a majority of the voting power of outstanding shares entitled to vote.
- Annual Meeting Results:
- Attendance: 11,578,018 shares were present (approximately 60.19% of outstanding shares).
- Director Elections: All seven nominees (Mina Sooch, Cam Gallagher, Sean Ainsworth, James Manuso, Richard Rodgers, Susan Benton, and Jay Pepose) were elected to one-year terms. Broker non-votes were significant, ranging from approximately 4.8 million shares per nominee.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. The primary disclosure relates to the procedural change in the quorum requirement for future stockholder meetings.
Investor Verification Checklist
- Verify the impact of the increased quorum requirement (from one-third to a majority) on the ability to hold future stockholder meetings.
- Review the full text of the Second Amendment to the Bylaws (Exhibit 3.1) for additional governance details.
- Confirm the composition of the newly elected Board of Directors and their terms.
- Note the high volume of broker non-votes in the director election, which may indicate institutional investor passivity or specific proxy voting instructions.